AstraZeneca (LSE:AZN) Stock Still Looks Like A Bargain Today

AstraZeneca has delivered a 59.1% gain over the past 5 years, yet the broader valuation checks still flag the stock as pricing in less optimism than many peers. With a recent pullback leaving the share price lower year to date, investors are weighing a softer near term run against signals that the market may be underpaying for the long term pipeline.

• The 59.1% return over 5 years points to solid long haul wealth creation, even though shorter term performance has been far more muted.
• Progress across oncology and respiratory drugs, including recent approvals and late stage trial wins, can support expectations for future cash flows, while execution risk around clinical outcomes and regulatory decisions may still cap how much investors are willing to pay today.
• AstraZeneca screens as undervalued on the broader checks, with a value score of 5. This suggests the current price leans cheap rather than fully pricing in the portfolio story.

The stock's next move may depend on whether the market keeps treating AstraZeneca as a cautious pipeline bet or starts to value it more in line with the long run returns it has already delivered.

Spot 14 high quality undervalued stocks that, like AstraZeneca after its recent pullback, still appear priced for caution despite solid long term return profiles.

Is AstraZeneca Still Cheap on Earnings?

The P/E ratio is useful here because AstraZeneca already reports earnings that investors can compare directly with the price you pay for each share.

Through this lens, AstraZeneca trades on a P/E of 23.4x, which is very close to the wider pharmaceuticals sector average of 22.5x. Against that broad yardstick, the stock looks roughly in line with the typical large drug maker. The peer group used in the model is richer at 44.4x, which indicates that investors in comparable businesses are currently paying a higher earnings multiple.

The more tailored fair P/E for AstraZeneca, which incorporates factors such as its risk profile, profitability and market size, is 43.4x. This is above the current 23.4x earnings multiple, so the shares appear to trade at a discount on this framework. Despite recent positive trial and approval news across oncology and respiratory treatments, the valuation is below both the peer average and the modelled fair level.

On a P/E basis, AstraZeneca appears undervalued, with the current earnings multiple below the level suggested by the fair ratio and by peers.

See what the numbers say about this price — find out in our valuation breakdown.

The AstraZeneca Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where AstraZeneca's valuation puzzle leaves off and spell out which paths for growth, margins and earnings would need to play out for the shares to be worth meaningfully more or less than today. Each scenario treats AstraZeneca's fair value as a thesis about how the business might perform that you can track over time, and they appear on the stock's Community page so you can see how those ideas evolve.

Community views on AstraZeneca are split between a rerating story and a reset story, with both leaning hard on the same oncology engine.

Bull case: 27% undervalued

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches over the next several years..."

Read the full Bull Case to see why AstraZeneca could be undervalued

Bear case: roughly fairly valued

"The looming expiration of patents on key blockbuster drugs like Tagrisso, Farxiga, and Imfinzi exposes AstraZeneca to biosimilar and generic competition that is almost certain to erode high-margin revenue streams..."

Read the full Bear Case to see why AstraZeneca could be overvalued

Do you think there's more to the story for AstraZeneca? Head over to our Community to see what others are saying!

The Bottom Line

AstraZeneca screens as undervalued on earnings, with the current P/E sitting well below the tailored fair multiple and the richer peer group used in the model. The valuation gap really comes down to whether the oncology and respiratory portfolio can keep justifying a higher earnings multiple as existing drugs mature and patent expiries get closer. If you think execution on late stage projects offsets that patent risk, the current discount may reflect the market being overly cautious. If those trials stumble or competition becomes more intense, the lower P/E may simply be the price the market assigns to that uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com